Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Preservation of beta-cell function following treatment with NN-414

Sep. 5, 2003

Glucocorticoid receptor modulators for obesity, diabetes, psychiatric disorders, etc.

Sep. 5, 2003

ICAgen completes enrollment in phase II trial of ICA-17043

Sep. 5, 2003

Orphan drug status granted to Hemoxin for sickle cell disease

Sep. 5, 2003

Phase I/II trial of bone graft product cleared to begin

Sep. 5, 2003

Oral efficacy study completed for small-molecule inhibitor of PTP1B

Sep. 5, 2003

HIM2 effects on glucose production and disposal in nondiabetic subjects

Sep. 4, 2003

New PPARalpha activator improves insulin sensitivity and lipid profiles in primates

Sep. 4, 2003

Avandia label expanded in Europe

Sep. 4, 2003

Mechanism of protective effects of pyridoxamine against diabetic nephropathy

Sep. 4, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...